Literature DB >> 27170759

Bile Acids Act as Soluble Host Restriction Factors Limiting Cytomegalovirus Replication in Hepatocytes.

Anna-Kathrin Schupp1, Mirko Trilling2,3, Stephanie Rattay2, Vu Thuy Khanh Le-Trilling2,3, Katrin Haselow1, Jan Stindt1, Albert Zimmermann2, Dieter Häussinger1, Hartmut Hengel4,5, Dirk Graf6.   

Abstract

UNLABELLED: The liver constitutes a prime site of cytomegalovirus (CMV) replication and latency. Hepatocytes produce, secrete, and recycle a chemically diverse set of bile acids, with the result that interactions between bile acids and cytomegalovirus inevitably occur. Here we determined the impact of naturally occurring bile acids on mouse CMV (MCMV) replication. In primary mouse hepatocytes, physiological concentrations of taurochenodeoxycholic acid (TCDC), glycochenodeoxycholic acid, and to a lesser extent taurocholic acid significantly reduced MCMV-induced gene expression and diminished the generation of virus progeny, while several other bile acids did not exert antiviral effects. The anticytomegalovirus activity required active import of bile acids via the sodium-taurocholate-cotransporting polypeptide (NTCP) and was consistently observed in hepatocytes but not in fibroblasts. Under conditions in which alpha interferon (IFN-α) lacks antiviral activity, physiological TCDC concentrations were similarly effective as IFN-γ. A detailed investigation of distinct steps of the viral life cycle revealed that TCDC deregulates viral transcription and diminishes global translation in infected cells. IMPORTANCE: Cytomegaloviruses are members of the Betaherpesvirinae subfamily. Primary infection leads to latency, from which cytomegaloviruses can reactivate under immunocompromised conditions and cause severe disease manifestations, including hepatitis. The present study describes an unanticipated antiviral activity of conjugated bile acids on MCMV replication in hepatocytes. Bile acids negatively influence viral transcription and exhibit a global effect on translation. Our data identify bile acids as site-specific soluble host restriction factors against MCMV, which may allow rational design of anticytomegalovirus drugs using bile acids as lead compounds.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27170759      PMCID: PMC4944301          DOI: 10.1128/JVI.00299-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  74 in total

1.  In vivo replication of recombinant murine cytomegalovirus driven by the paralogous major immediate-early promoter-enhancer of human cytomegalovirus.

Authors:  N K Grzimek; J Podlech; H P Steffens; R Holtappels; S Schmalz; M J Reddehase
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  Human cytomegalovirus stimulates host cell RNA synthesis.

Authors:  S Tanaka; T Furukawa; S A Plotkin
Journal:  J Virol       Date:  1975-02       Impact factor: 5.103

3.  CMV hepatitis after liver transplantation: incidence, clinical course, and long-term follow-up.

Authors:  Daniel Seehofer; Nada Rayes; Stefan G Tullius; Christian A Schmidt; Ulf P Neumann; Cornelia Radke; Utz Settmacher; Andrea R Müller; Thomas Steinmüller; Peter Neuhaus
Journal:  Liver Transpl       Date:  2002-12       Impact factor: 5.799

4.  Conjugated and unconjugated serum bile acid levels n patients with hepatobiliary diseases.

Authors:  I Makino; S Nakagawa; K Mashimo
Journal:  Gastroenterology       Date:  1969-06       Impact factor: 22.682

5.  Taurolithocholic acid-3 sulfate induces CD95 trafficking and apoptosis in a c-Jun N-terminal kinase-dependent manner.

Authors:  Dirk Graf; Anna Kordelia Kurz; Richard Fischer; Roland Reinehr; Dieter Häussinger
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

6.  Myc Regulation of mRNA Cap Methylation.

Authors:  Victoria H Cowling; Michael D Cole
Journal:  Genes Cancer       Date:  2010-06

7.  Persistent cytomegalovirus in liver allografts with chronic rejection.

Authors:  I Lautenschlager; K Höckerstedt; H Jalanko; R Loginov; K Salmela; E Taskinen; J Ahonen
Journal:  Hepatology       Date:  1997-01       Impact factor: 17.425

8.  Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease.

Authors:  Carsten Gnewuch; Gerhard Liebisch; Thomas Langmann; Benjamin Dieplinger; Thomas Mueller; Meinhard Haltmayer; Hans Dieplinger; Alexandra Zahn; Wolfgang Stremmel; Gerhard Rogler; Gerd Schmitz
Journal:  World J Gastroenterol       Date:  2009-07-07       Impact factor: 5.742

9.  Vectorial transport of bile salts across MDCK cells expressing both rat Na+-taurocholate cotransporting polypeptide and rat bile salt export pump.

Authors:  Sachiko Mita; Hiroshi Suzuki; Hidetaka Akita; Bruno Stieger; Peter J Meier; Alan F Hofmann; Yuichi Sugiyama
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2004-08-05       Impact factor: 4.052

10.  Evaluating Human T-Cell Therapy of Cytomegalovirus Organ Disease in HLA-Transgenic Mice.

Authors:  Simone Thomas; Sebastian Klobuch; Jürgen Podlech; Bodo Plachter; Petra Hoffmann; Angelique Renzaho; Matthias Theobald; Matthias J Reddehase; Wolfgang Herr; Niels A W Lemmermann
Journal:  PLoS Pathog       Date:  2015-07-16       Impact factor: 6.823

View more
  8 in total

1.  The Intestinal Microbiome Restricts Alphavirus Infection and Dissemination through a Bile Acid-Type I IFN Signaling Axis.

Authors:  Emma S Winkler; Swathi Shrihari; Barry L Hykes; Scott A Handley; Prabhakar S Andhey; Yan-Jang S Huang; Amanda Swain; Lindsay Droit; Kranthi K Chebrolu; Matthias Mack; Dana L Vanlandingham; Larissa B Thackray; Marina Cella; Marco Colonna; Maxim N Artyomov; Thaddeus S Stappenbeck; Michael S Diamond
Journal:  Cell       Date:  2020-07-14       Impact factor: 41.582

2.  Structural Basis for Human Norovirus Capsid Binding to Bile Acids.

Authors:  Turgay Kilic; Anna Koromyslova; Grant S Hansman
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

3.  The intestinal regionalization of acute norovirus infection is regulated by the microbiota via bile acid-mediated priming of type III interferon.

Authors:  Katrina R Grau; Shu Zhu; Stefan T Peterson; Emily W Helm; Drake Philip; Matthew Phillips; Abel Hernandez; Holly Turula; Philip Frasse; Vincent R Graziano; Craig B Wilen; Christiane E Wobus; Megan T Baldridge; Stephanie M Karst
Journal:  Nat Microbiol       Date:  2019-11-25       Impact factor: 17.745

Review 4.  Environmental Restrictions: A New Concept Governing HIV-1 Spread Emerging from Integrated Experimental-Computational Analysis of Tissue-Like 3D Cultures.

Authors:  Samy Sid Ahmed; Nils Bundgaard; Frederik Graw; Oliver T Fackler
Journal:  Cells       Date:  2020-04-30       Impact factor: 6.600

5.  Anti-inflammatory consequences of bile acid accumulation in virus-infected bile duct ligated mice.

Authors:  Stephanie Rattay; Dirk Graf; Andreas Kislat; Bernhard Homey; Diran Herebian; Dieter Häussinger; Hartmut Hengel; Albert Zimmermann; Anna-Kathrin Schupp
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

6.  Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8+ T and NK cell function.

Authors:  Zhen Xun; Jinpiao Lin; Qingqing Yu; Can Liu; Jinlan Huang; Hongyan Shang; Jianhui Guo; Yuchen Ye; Wennan Wu; Yongbin Zeng; Songhang Wu; Siyi Xu; Tianbin Chen; Jing Chen; Qishui Ou
Journal:  Cell Mol Immunol       Date:  2021-01-11       Impact factor: 11.530

7.  Alterations in bile acids as metabolic signatures in the patients with human adenovirus type 7 infection.

Authors:  Wen Xu; Juan Du; Ting-Ting Wei; Lin-Yi Chen; Xin-Xin Yang; Tu Bo; Han-Yu Liu; Ming-Zhu Xie; Tian-Shuo Zhao; Jun-Lian Yang; Fuqiang Cui; Wei-Wei Chen; Qing-Bin Lu
Journal:  Front Med (Lausanne)       Date:  2022-09-07

Review 8.  The influence of microbiota-derived metabolites on viral infections.

Authors:  Ajisha Alwin; Stephanie M Karst
Journal:  Curr Opin Virol       Date:  2021-06-16       Impact factor: 7.121

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.